Graham J. Riley

5.6k total citations
70 papers, 4.1k citations indexed

About

Graham J. Riley is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Organic Chemistry. According to data from OpenAlex, Graham J. Riley has authored 70 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Molecular Biology, 32 papers in Cellular and Molecular Neuroscience and 23 papers in Organic Chemistry. Recurrent topics in Graham J. Riley's work include Receptor Mechanisms and Signaling (35 papers), Neurotransmitter Receptor Influence on Behavior (20 papers) and Pharmacological Receptor Mechanisms and Effects (10 papers). Graham J. Riley is often cited by papers focused on Receptor Mechanisms and Signaling (35 papers), Neurotransmitter Receptor Influence on Behavior (20 papers) and Pharmacological Receptor Mechanisms and Effects (10 papers). Graham J. Riley collaborates with scholars based in United Kingdom, United States and Italy. Graham J. Riley's co-authors include Steven M. Bromidge, Derek N. Middlemiss, Tania O. Stean, Ian T. Forbes, Vicky Holland, David R. Thomas, Jim J. Hagan, Martyn Wood, Gary Price and Neil Upton and has published in prestigious journals such as The Lancet, Journal of Medicinal Chemistry and Journal of Neurochemistry.

In The Last Decade

Graham J. Riley

70 papers receiving 3.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Graham J. Riley United Kingdom	31	2.3k	1.8k	797	779	458	70	4.1k
Robert J. Naylor United Kingdom	39	2.9k 1.3×	2.0k 1.1×	416 0.5×	518 0.7×	488 1.1×	134	4.9k
Douglas W. Bonhaus United States	31	2.2k 0.9×	1.6k 0.9×	292 0.4×	477 0.6×	333 0.7×	78	3.6k
Bjarke Ebert Denmark	37	2.7k 1.2×	1.9k 1.0×	473 0.6×	707 0.9×	773 1.7×	125	4.5k
Thomas P. Blackburn United States	30	2.2k 0.9×	1.6k 0.8×	330 0.4×	347 0.4×	440 1.0×	70	3.6k
Valérie Audinot France	37	2.5k 1.1×	2.1k 1.1×	534 0.7×	359 0.5×	382 0.8×	98	4.7k
Aaron Janowsky United States	43	3.5k 1.5×	2.6k 1.4×	430 0.5×	649 0.8×	426 0.9×	129	5.5k
Angelo Reggiani Italy	34	2.0k 0.9×	1.7k 0.9×	310 0.4×	1.1k 1.4×	451 1.0×	99	4.0k
Erik H.F. Wong United States	40	4.9k 2.1×	3.7k 2.0×	561 0.7×	673 0.9×	857 1.9×	91	6.9k
Luís F. Callado Spain	35	2.1k 0.9×	1.7k 0.9×	329 0.4×	888 1.1×	332 0.7×	170	3.9k
Marius C. Hoener Switzerland	45	4.1k 1.8×	3.0k 1.6×	468 0.6×	613 0.8×	439 1.0×	94	6.7k

Countries citing papers authored by Graham J. Riley

Since Specialization

Citations

This map shows the geographic impact of Graham J. Riley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Graham J. Riley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Graham J. Riley more than expected).

Fields of papers citing papers by Graham J. Riley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Graham J. Riley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Graham J. Riley. The network helps show where Graham J. Riley may publish in the future.

Co-authorship network of co-authors of Graham J. Riley

This figure shows the co-authorship network connecting the top 25 collaborators of Graham J. Riley. A scholar is included among the top collaborators of Graham J. Riley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Graham J. Riley. Graham J. Riley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wood, Martyn, Claire M. Scott, Nisha Patel, et al.. (2006). Pharmacological Profile of Antipsychotics at Monoamine Receptors: Atypicality Beyond 5-HT2A Receptor Blockade. CNS & Neurological Disorders - Drug Targets. 5(4). 445–452. 30 indexed citations

Bromidge, Steven M., David Clapham, Frank D. King, et al.. (2005). A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 15(22). 4989–4993. 14 indexed citations

Thomas, David R., Sergio Melotto, Andrew D. Gribble, et al.. (2003). SB‐656104‐A, a novel selective 5‐HT₇ receptor antagonist, modulates REM sleep in rats. British Journal of Pharmacology. 139(4). 705–714. 101 indexed citations

Forbes, Ian T., David G. Cooper, Andrew D. Gribble, et al.. (2003). Identification of a novel series of selective 5-HT7 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 13(6). 1055–1058. 16 indexed citations

Duxon, Mark, Kathryn R. Starr, Declan N.C. Jones, et al.. (2001). Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX 1 ) receptors, with downstream 5-HT 2C receptor involvement. Psychopharmacology. 153(2). 203–209. 79 indexed citations

Wood, Martyn, Charlie Reavill, Brenda Trail, et al.. (2001). SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology. 41(2). 186–199. 78 indexed citations

Hagan, Jim J., Gary Price, Philip D. Jeffrey, et al.. (2000). Characterization of SB‐269970‐A, a selective 5‐HT₇ receptor antagonist. British Journal of Pharmacology. 130(3). 539–548. 254 indexed citations

Bromidge, Steven M., Steven Dabbs, Susannah Davies, et al.. (2000). 1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/Anxiolytic agents. Bioorganic & Medicinal Chemistry Letters. 10(16). 1863–1866. 16 indexed citations

Wood, Martyn, et al.. (2000). Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. European Journal of Pharmacology. 407(1-2). 47–51. 58 indexed citations

10.

Avenell, Kim Y., Izzy Boyfield, Michael S. Hadley, et al.. (1999). Heterocyclic analogues of 2-aminotetralins with high affinity and selectivity for the dopamine D3 receptor. Bioorganic & Medicinal Chemistry Letters. 9(18). 2715–2720. 14 indexed citations

11.

Bromidge, Steven M., Steven Dabbs, David T. Davies, et al.. (1998). Novel and Selective 5-HT_2C/2B Receptor Antagonists as Potential Anxiolytic Agents: Synthesis, Quantitative Structure−Activity Relationships, and Molecular Modeling of Substituted 1-(3-Pyridylcarbamoyl)indolines. Journal of Medicinal Chemistry. 41(10). 1598–1612. 53 indexed citations

12.

Thomas, David R., Derek N. Middlemiss, Graham J. Riley, et al.. (1998). Functional characterisation of the human cloned 5‐HT₇ receptor (long form); antagonist profile of SB‐258719. British Journal of Pharmacology. 124(6). 1300–1306. 103 indexed citations

13.

Bromidge, Steven M., Frank Brown, Frederick Cassidy, et al.. (1997). Design of [R-(Z)]-(+)-α-(Methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitrile (SB 202026), a Functionally Selective Azabicyclic Muscarinic M1 Agonist Incorporating the N-Methoxy Imidoyl Nitrile Group as a Novel Ester Bioisostere. Journal of Medicinal Chemistry. 40(26). 4265–4280. 22 indexed citations

14.

Kennett, G.A., Martyn Wood, Fiona Bright, et al.. (1997). SB 242084, a Selective and Brain Penetrant 5-HT 2C Receptor Antagonist. Neuropharmacology. 36(4-5). 609–620. 455 indexed citations

15.

Boyfield, Izzy, Martyn C. Coldwell, Michael S. Hadley, et al.. (1996). Novel 2,5-disubstituted-1H-pyrroles with high affinity for the dopamine D3 receptor. Bioorganic & Medicinal Chemistry Letters. 6(11). 1233–1236. 10 indexed citations

16.

Bromidge, Steven M., Frederick Cassidy, Michael Clark, et al.. (1994). Bridged 1,2,5,6-tetrahydropyridine esters and oxime ethers related to arecoline are novel and potent muscarinic agonists. Bioorganic & Medicinal Chemistry Letters. 4(10). 1185–1190. 1 indexed citations

17.

Orlek, Barry S., et al.. (1994). Design and synthesis of novel muscarinic agonists containing the 1,2,4-triazine ring as an ester bioisostere. Bioorganic & Medicinal Chemistry Letters. 4(12). 1411–1414. 7 indexed citations

18.

Wadsworth, Harry J., S. M. Jenkins, Barry S. Orlek, et al.. (1992). Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. Journal of Medicinal Chemistry. 35(7). 1280–1290. 68 indexed citations

19.

Orlek, Barry S., Frank E. Blaney, Frank Brown, et al.. (1991). Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor. Journal of Medicinal Chemistry. 34(9). 2726–2735. 171 indexed citations

20.

Brown, Frank, William Campbell, Michael Clark, et al.. (1988). The selective dopamine antagonist properties of BRL 34778: a novel substituted benzamide. Psychopharmacology. 94(3). 350–8. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact